Hormone Receptor Negative Breast Cancer

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or HR Negative #MetastaticBreast #cancer and Her-2 Testing in #breastcancer: @ASCO Guideline Rapid Recommendation Update Q and A https://t.co/aWVwsnwNsl @JCOOP_ASCO @OncoAlert @BeverlyMoy @awolff (@jamecancerdoc)

It’s awesome that you’re pro-breast cancer man, what other weird shit are you into? (@McclureOregon)

#CCTG MA41 (DECRESCENDO) breast cancer study opens in Canada. Investigating a less intensive treatment for patients with HER2-positive, ER-negative and node negative #breastcancer @Philippe_Bedard @BIGagainstBC @UHN @pmcancercentre #SolvingCancerTogether https://t.co/niNF9sgeAT (@CDNCancerTrials)

Women with ER-negative primary breast cancers are at higher risk of second breast cancers than women with ER-positive cancers during the first 5 years after diagnosis. Read more: https://t.co/Ppp5HmrLrd @oncoalert @oreganruth #BCSM (@JournalCancer)

Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for BRCA1, 27% for BRCA2, and 13% for CHEK2 PV carriers with breast cancer and 35% for PALB2 PV carriers with ER-negative breast cancer. https://t.co/i8UatunHqR (@KefahMokbel)

Genomic and Transcriptomic landscape of HER2-low breast cancer @SABCS2023 Bansal R H2L subset largely shared genomic features of HR+ or HR- breast cancers #HER2Low (@ChivukulaMd)

Contralateral breast cancer (CBC) risk in germline pathogenic variant carriers 🧬BRCA1, BRCA2 & CHEK2: > 2-fold ⬆️ risk 🧬ATM: CBC risk not increased↔️ 🧬PALB2: Only PV carriers with ER-negative breast cancer were at ⬆️ risk #SABCS22 @OncoAlert @SidYadavMD (@DrSGraff)

@JimAllisonPhD @CancerCureDoc @LillyPad @AstraZeneca @PamSharmaMDPhD @Dr_RShatsky @VivekSubbiah @aditishasMD @teamoncology Dear Doctors please help which immunotherapy works on ER negative breast cancer, my wife is sick (@AVESHT1)

While #pathologic complete response rates were numerically higher in the PGM treatment arm for hormone receptor-negative, #HER2-negative #breastcancer (32% versus 21%), this small increase did not meet I-SPY’s prespecified threshold for graduation🤔📑 (@Dr_Ivanoncologo)

ASCO Guideline Update: Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic #BreastCancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative https://t.co/rdKpSF6ymD #JCO #BCSM @BeverlyMoy @DrLisaCarey (@ASCO_pubs)

In women with #breastcancer > 65: BRCA1, BRCA2, and PALB2 were found in: ✅3.42% of those with ER negative ✅1.0% with ER positive ✅3.01% with #tnbc #bcsm @ASCO_pubs @OncoAlert (@maryam_lustberg)

Pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 associated with increased risks of #breastcancer and BARD1, RAD51C, and RAD51D were associated with increased risks of ER-negative BC @OncoAlert #bcsm https://t.co/WHoWs1hBCx @NEJM (@jamecancerdoc)

What? We use neoadjuvant chemotherapy in breast cancer all the time. I can find, with little effort, scads of articles showing its benefit, especially in hormone receptor negative and HER2+ cancer.🤦🏻‍♂️ (@gorskon)

Dr. Sara Tolaney @stolaney1 of @DanaFarber joined us for the discussion of a 39-year-old woman with relapsed/refractory HR-negative/HER2-positive metastatic breast cancer. https://t.co/ET6gnhN2GW #TargetedChat #BreastCancer #bcsm (@TargetedOnc)